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Abstract: 
 
Hair loss is a common symptom resulting from a wide range of disease processes and can lead to 
stress in affected individuals. The purpose of this study was to examine the effect of fullerene 
nanomaterials on hair growth. We used shaved mice as well as SKH-1 “bald” mice to determine 
if fullerene-based compounds could affect hair growth and hair follicle numbers. In shaved mice, 
fullerenes increase the rate of hair growth as compared with mice receiving vehicle only. In 
SKH-1 hairless mice fullerene derivatives given topically or subdermally markedly increased 
hair growth. This was paralleled by a significant increase in the number of hair follicles in 
fullerene-treated mice as compared with those mice treated with vehicle only. The fullerenes also 
increased hair growth in human skin sections maintained in culture. These studies have wide-
ranging implications for those conditions leading to hair loss, including alopecia, chemotherapy, 
and reactions to various chemicals. 
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Abbreviations 
 
DMSO: Dimethyl sulfoxide 
DGME: Di ethylene Glycol Monomethyl Ether 
MALDI-MS: Matrix Assisted Laser Desorption Ionization Mass Spectrometry 
NMR: Nuclear Magnetic Resonance 
HPLC: High Performance Liquid Chromatography 
 
There are three stages of hair growth: anagen (the growing phase), catagen (the regressing 
phase), and telogen (the resting phase). The transformations from each phase are controlled by 
changes in the local signaling milieu, based on changes in expression/activity of several 
cytokines, hormones, neurotransmitters, transcription factors, and enzymes that induce hair 
follicle cycling.1 These controls of hair follicle cycling are of great clinical interest, because hair 
loss is a common symptom resulting from ailments, such as male/female pattern balding and 
therapies aimed to treat certain diseases that result in hair loss (e.g., radiotherapy and 
chemotherapy). Although the hair follicle seems to be the main control point for cycling, the 
exact underlying molecular mechanisms that drive the formation of follicles remain unclear. 
Thus far it is not known what signal(s) initiate hair follicle formation.2, 3 
 
Fullerenes are carbon spheres that have intrinsic properties that may have therapeutic potential 
for a wide range of disorders.4, 5 For example, water-soluble C60 molecules have been shown to 
extend the life span of mice through the reduction in oxidative stress,6 improve cognitive 
function in neurological disorders,7 and are potential treatments for allergic disease.8 
 
Given the multitude of signaling molecules affected by these molecules,8 we hypothesized that 
the fullerenes could affect the underlying mechanisms that initiate hair follicle formation and 
hair growth. We report that fullerene derivatives accelerate the growth of hair in mice and human 
skin. In addition, these molecules significantly increase the number of hair follicles in the skin of 
mice genetically deficient in follicle formation. The later finding represents a potentially new 
therapeutic opportunity for conditions leading to hair loss. 
 
Methods 
 
Materials 
 
All mice (8-week-old males) were purchased from Charles River Laboratories (Wilmington, 
Massachusetts) and humanely treated under standard conditions. All studies were approved by 
the Institutional Review Board at Hamner Institute of Health Science (Research Triangle Park, 
North Carolina). Mice (C57/B6) were shaved on the interscapular part of the back. To examine 
the induction of hair growth we also used SKH-1 mice (nude), which are euthymic and immune 
competent. SKH-1 hairless mice were chosen for the study, because they provide a background 
on which changes in hair growth and follicle number can be easily assessed. SKH-1 mice lose all 
external hair in their first hair cycle after birth, so that all the tested mice are in the same stage of 
the hair growth cycle. The presence of a small number of hair follicles in telogen phase was 
observed histologically, as has been described elsewhere in these mice.9 
 
Fullerene derivatives (a general structure is given in Figure 1) were synthesized and 
characterized using matrix-assisted laser desorption ionization mass spectrometry, nuclear 
magnetic resonance, and high performance liquid chromatography. A description of the synthesis 
and characterization is described elsewhere (unpublished data). The fullerene derivatives or 
controls, in phosphate-buffered saline (PBS), were injected intradermally using a 0.4-mL 
tuberculin syringe. Alternatively, fullerene derivatives were applied topically in dimethyl 
sulfoxide (DMSO), or di ethylene glycol monomethyl ether (DGME) on the interscapular part of 
the mouse back (using a 0.5-mL syringe) every other day for up to 14 days. After 
photodocumentation, mice were killed and the skin and hair were removed from the test area, 
fixed in 4% paraformaldehyde, and sectioned for histochemical analysis using hematoxylin and 
eosin (H&E). The number of hair follicles per square millimeter was quantitated by light 
microscopy by a blinded observer. 
 
 
Figure 1. Representative 3D visualization of fullerene derivative. 
 
For studies with human skin, tissue was obtained anonymously by the Cooperative Human 
Tissue Network (CHTN; Charlottesville, Virginia). All studies were exempt and approved by the 
Institutional Review Committee at CHTN. Samples were cut into 1-cm2 sections, so that the 
epidermis, dermis, and subcutis remained intact together. Triplicate sections were placed in 1 mL 
of Ex-Vivo (Lonza, Walkersville, Maryland; with penicillin/streptomycin and l-glutamine) with 
or without 10 μg/mL of fullerene for 14 days, with fresh medium added every fourth day. After 
removing any subcutaneous adipose tissue, sections were placed on slides and coverslips pressed 
down over the skin so as to minimize the section thickness. Hair numbers were quantitated and 
photo documented using a 4× objective lens and counting the number of hairs per square 
centimeter. Adjacent sections from before and after treatment were fixed in 4% 
paraformaldehyde and H&E slides obtained for hair follicle quantitation. 
 
Results 
 
Although fullerenes have certain intrinsic properties that make them attractive candidates for 
therapeutic development, they are not water soluble and they nonspecifically accumulate within 
cells. We developed several amphiphilic fullerenes that are hypothesized to target intracellular 
membranes to test in preclinical hair growth models. We first tested the fullerene derivatives for 
their ability to affect hair growth on mice that had been shaved bald in the interscapular part of 
the back. Mice were injected with fullerenes or vehicle only subcutaneously every other day for 
up to 14 days. As seen in Figure 2, A and B, mice injected with fullerene derivatives had 
accelerated hair growth as compared with those mice receiving vehicle only. The effects of 
fullerene derivatives on mice genetically deficient in hair follicle formation and hair was also 
examined. As seen in Figure 2, C and D, mice injected every other day had significantly more 
hair strands as compared with those mice injected with vehicle only. Similar results were 
obtained using the same compound dissolved in DMSO (Figure 2, E and F). This enhancement 
was paralleled by a marked increase in the number of hair follicles within the dermis (Figure 
3, A and B compared to Figure 3, C and D). Quantification of the number of hair follicles in 
treated vs. nontreated animals revealed a statistically significant increase in fullerene-treated 
mice when given intradermally (Figure 4, A) or topically (Figure 4, B). Thus, fullerenes not only 
accelerate the rate at which hair shafts grow but also induce de novo synthesis of new hair 
follicles. 
 
 
Figure 2. Fullerene nanomaterials enhance hair growth. C57 mice (A, B) were shaved bald using 
a straight-edge razor. PBS (A) or 3 μg of fullerenes in 300 μL of PBS (B)were injected every 
other day for 12 days. SKH-1 bald mice (C, D) were injected every other day with PBS (C) or 3 
μg of fullerenes in 300 μL PBS (D). All injections were administered intradermally, and pictures 
were taken at day 14. In some experiments DMSO (E) or fullerenes in DMSO (F) were applied 
topically. Experiment is representative of six different mice. 
 
 
Figure 3. Fullerene nanomaterials increase hair follicle numbers. SKH-1 mice were treated as in 
Figure 2 with PBS (A, B) or fullerenes (C, D). Skin sections were taken from the injection area 
and stained with H&E. Arrows indicate the presence of hair follicles (10× magnification). 
 
 
Figure 4. Quantification of newly generated hair follicles. Mice (n = 6) were treated 
intradermally (A) or topically (B) as in Figure 2 and the number of hair follicles counted using 
microscopy by an observer blinded to the content of the injections. The results represent the 
average number of hair follicles per square millimeter in treated (black box) and untreated (white 
box) mice (±SEM). Significance was determined using the Student's t-test. 
 
To determine if the fullerene could induce hair growth from human skin, we incubated human 
skin sections in medium with or without fullerenes. As seen in Figure 5, there was a significant 
increase in the number of hairs visualized in the skin sections incubated for 14 days with 
fullerenes as compared with those sections incubated in medium alone. Thus, fullerene 
derivatives stimulate hair growth in human skin. 
 
 
Figure 5. Fullerenes induce hair growth in human skin. Human skin sections (n = 3) were 
submersed in medium with or without fullerenes (10 μg/mL) for 14 days. Slides were made of 
the entire section and the number of hairs counted using microscopy. Pictures of the intact 
epidermis from control (A) and treated (B, C) skin sections are shown at a magnification of 4×. 
The results in the bar graph (D) represent the average number of hairs per square centimeter in 
treated (black box) and untreated (white box) mice (±SEM). Significance was determined using 
the Student's t-test. 
 
Discussion 
 
The loss of hair is a widespread problem in both women and men that can cause emotional stress 
and low self-esteem for affected individuals. Although the vast majority of hair loss is due to 
underlying genetic predispositions, several other factors can accelerate the process. Certain 
illnesses or a major surgery, hormonal problems, overactive or underactive thyroid disease, 
certain medicines, and infections can all lead to hair loss. The problem is that there are limited 
effective treatments that can prevent hair loss and induce new hair growth. In this report we 
show that fullerene derivatives can accelerate hair strand growth and induce new hair follicles 
within the dermis in mice with genetically underlying factors that limit hair follicle numbers and 
hair growth. Thus, these compounds may represent a new way to treat hair loss. 
 
As with minoxidil (Rogaine) and finasteride (Propecia), the only two hair loss treatments 
approved by the US Food and Drug Administration, it is unclear how fullerenes induce hair 
growth. In animal studies, minoxidil shortens telogen, causing premature entry of resting hair 
follicles into anagen, and causes prolongation of anagen, thus increasing hair follicle 
size.10 Finasteride is an anti-androgen that inhibits human type 2 5α-reductase and decreases the 
formation of dihydrotestosterone from testosterone. However, neither minoxidil nor finasteride 
seems to have any significant effect on hair follicle numbers in hairless mice and human scalp 
tissue.11, 12, 13 In contrast, we have discovered a new way in which hair follicles can be induced 
de novo. As seen above, the fullerene derivatives described here significantly increase the 
number of hair follicles in the skin. 
 
Oxidative stress through the production of reactive oxygen species (ROS) is thought to be a 
significant underlying factor in aging and has been shown to be present in human hair.14, 15 
Intriguingly, the continuous melanin synthesis in the growing (anagen) hair follicle generates 
high oxidative stress, which leads to their selective premature aging and apoptosis. In addition, a 
direct correlation between hair loss and oxidative stress has been implied in studies of patients 
with alopecia.16 The fullerene core can react with free-radical species given its capacity to absorb 
electrons and disperse them through the 20 benzene rings distributed over its surface. In fact, it is 
one of the most potent free-radical scavengers known, with the potential for being “sponges” in 
diseases involving ROS,5 making them attractive therapeutic options in acute and chronic 
neurodegenerative diseases such as Parkinson's, Alzheimer's, and Lou Gehrig's, which involve 
ROS.7, 17, 18 We recently showed that fullerenes can prevent allergic responses in vitro and in 
vivo, probably through the inhibition of ROS.8 Thus, it is possible that fullerenes prevent the 
oxidative stress associated with hair follicle degradation. We are currently investigating the 
mechanisms of how fullerenes induce hair regeneration. 
 
There is little evidence to suggest that the mouse hair cycle differs structurally in any way from 
the human hair follicle cycle.19 Indeed, we demonstrate that fullerenes induce hair growth in 
human skin, suggesting that the mechanism that potentiates hair growth in mice is similar to that 
in humans. Thus, we predict the results presented here will translate into new ways to induce hair 
growth in the approximately 20% to 50% of individuals in whom minoxidil and finasteride have 
no effect.13, 20, 21, 22 
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